KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $111.4 million.

  • BeOne Medicines' Change in Accured Expenses rose 8.89% to $90.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.6 million, marking a year-over-year increase of 20.55%. This contributed to the annual value of $111.4 million for FY2024, which is 38.17% down from last year.
  • Latest data reveals that BeOne Medicines reported Change in Accured Expenses of $111.4 million as of FY2024, which was down 38.17% from $180.1 million recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Change in Accured Expenses ranged from a high of $236.7 million in FY2021 and a low of $45.6 million during FY2022.
  • For the 3-year period, BeOne Medicines' Change in Accured Expenses averaged around $112.4 million, with its median value being $111.4 million (2024).
  • As far as peak fluctuations go, BeOne Medicines' Change in Accured Expenses slumped by 80.73% in 2022, and later surged by 294.75% in 2023.
  • Yearly analysis of 5 years shows BeOne Medicines' Change in Accured Expenses stood at $185.0 million in 2020, then increased by 27.96% to $236.7 million in 2021, then slumped by 80.73% to $45.6 million in 2022, then surged by 294.75% to $180.1 million in 2023, then tumbled by 38.17% to $111.4 million in 2024.